Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scanner could halve repeat breast cancer surgeries

NCT ID NCT07527468

Symptom relief Sponsor: Hôpital du Valais Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a special scanner that lets surgeons check, in real time during breast cancer surgery, whether all cancer has been removed. The goal is to reduce the need for a second operation. About 228 women with certain high-risk breast cancer types will take part. The scanner is already approved for use, and this study will see if it cuts the repeat surgery rate from about 11% to 5% or less.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Histolog Scanner (a confocal fluorescence microscopy device used during surgery to check if all cancer has been removed)
What this could lead to
If successful, this device could help surgeons remove all cancer in one operation, reducing the need for a second surgery and its associated stress and recovery time.
What could go wrong
This is a relatively small, single-center study comparing results to past cases, not a randomized trial. The device may not work as well in all patients or tumor types, and the final decision for reoperation is made independently, so the device's impact may be limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 228 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jun 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

1. Female patient, aged 18 years or older at time of surgery. 2. Pre-operative core needle biopsy (CNB) or vacuum-assisted biopsy (VAB) with histological diagnosis of one of the following: 1. invasive lobular carcinoma (ILC/CLI), 2. pure ductal carcinoma in situ (DCIS), or 3. invasive carcinoma of non-special type (NST) with an associated DCIS component. 3. Planned breast-conserving surgery (BCS / lumpectomy) at CHVR. 4. Signed electronic informed consent (eIC) obtained prior to any study procedure. Exclusion Criteria: 1. Pregnancy (confirmed or suspected) at time of surgery. 2. Prior neo-adjuvant treatment (hormonal therapy or chemotherapy) for the current breast cancer diagnosis. 3. Surgical indication for mastectomy rather than BCS. 4. Known hypersensitivity or allergy to acriflavine (fluorescent staining agent used with the Histolog Scanner). 5. Incapacity to provide informed consent. 6. Previous enrolment in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Carcinoma, Lobular ductal breast carcinoma in situ invasive ductal breast carcinoma invasive lobular breast carcinoma Margins of Excision

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Breast neoplasm female Ductal carcinoma in situ Invasive lobular carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier du Valais Romand (CHVR)

    Sion, Valais, 1950, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.